Literature DB >> 26975530

Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a).

Margaret R Diffenderfer1, Stefania Lamon-Fava2, Santica M Marcovina3, P Hugh R Barrett4, Julian Lel5, Gregory G Dolnikowski6, Lars Berglund7, Ernst J Schaefer8.   

Abstract

OBJECTIVES: Lipoprotein(a) [Lp(a)] is mainly similar in composition to LDL, but differs in having apolipoprotein (apo) (a) covalently linked to apoB-100. Our purpose was to examine the individual metabolism of apo(a) and apoB-100 within plasma Lp(a).
MATERIALS AND METHODS: The kinetics of apo(a) and apoB-100 in plasma Lp(a) were assessed in four men with dyslipidemia [Lp(a) concentration: 8.9-124.7nmol/L]. All subjects received a primed constant infusion of [5,5,5-(2)H3] L-leucine while in the constantly fed state. Lp(a) was immunoprecipitated directly from whole plasma; apo(a) and apoB-100 were separated by gel electrophoresis; and isotopic enrichment was determined by gas chromatography/mass spectrometry.
RESULTS: Multicompartmental modeling analysis indicated that the median fractional catabolic rates of apo(a) and apoB-100 within Lp(a) were significantly different at 0.104 and 0.263 pools/day, respectively (P=0.04). The median Lp(a) apo(a) production rate at 0.248nmol/kg·day(-1) was significantly lower than that of Lp(a) apoB-100 at 0.514nmol/kg·day(-1) (P=0.03).
CONCLUSION: Our data indicate that apo(a) has a plasma residence time (11days) that is more than twice as long as that of apoB-100 (4days) within Lp(a), supporting the concept that apo(a) and apoB-100 within plasma Lp(a) are not catabolized from the bloodstream as a unit in humans in the fed state.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fed state; Hypertriglyceridemia; Kinetics; Lipoprotein(a)

Mesh:

Substances:

Year:  2015        PMID: 26975530      PMCID: PMC4795479          DOI: 10.1016/j.metabol.2015.10.031

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  54 in total

Review 1.  Lipoprotein(a): intrigues and insights.

Authors:  H H Hobbs; A L White
Journal:  Curr Opin Lipidol       Date:  1999-06       Impact factor: 4.776

2.  A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM.

Authors:  K BERG
Journal:  Acta Pathol Microbiol Scand       Date:  1963

Review 3.  Heterogeneity of lipoprotein (a): growing complexities.

Authors:  O Klezovitch; A M Scanu
Journal:  Curr Opin Lipidol       Date:  1995-08       Impact factor: 4.776

4.  Changes in the concentration and distribution of lipoprotein (a) in plasma after fat intake.

Authors:  T Ishikawa; T Yamashita; K Mochizuki; K Suzuki; N Hashizume; H Nakamura
Journal:  J Atheroscler Thromb       Date:  1995       Impact factor: 4.928

5.  Association of Lp(a) rather than integrally-bound apo(a) with triglyceride-rich lipoproteins of human subjects.

Authors:  C Marcoux; S Lussier-Cacan; J Davignon; J S Cohn
Journal:  Biochim Biophys Acta       Date:  1997-06-23

6.  The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.

Authors:  D J Rader; W Cain; K Ikewaki; G Talley; L A Zech; D Usher; H B Brewer
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

7.  Evidence that Lp[a] contains one molecule of apo[a] and one molecule of apoB: evaluation of amino acid analysis data.

Authors:  J J Albers; H Kennedy; S M Marcovina
Journal:  J Lipid Res       Date:  1996-01       Impact factor: 5.922

8.  Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature.

Authors:  S M Marcovina; H H Hobbs; J J Albers
Journal:  Clin Chem       Date:  1996-03       Impact factor: 8.327

9.  Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement.

Authors:  W Su; H Campos; H Judge; B W Walsh; F M Sacks
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

10.  Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a).

Authors:  S M Marcovina; J J Albers; B Gabel; M L Koschinsky; V P Gaur
Journal:  Clin Chem       Date:  1995-02       Impact factor: 8.327

View more
  7 in total

1.  The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Kun Yue; Ching-Shang Li; Lars Berglund
Journal:  J Lipid Res       Date:  2017-08-10       Impact factor: 5.922

2.  Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a).

Authors:  Justin R Clark; Matthew Gemin; Amer Youssef; Santica M Marcovina; Annik Prat; Nabil G Seidah; Robert A Hegele; Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2022-04-22       Impact factor: 6.676

3.  Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.

Authors:  Gissette Reyes-Soffer; Marianna Pavlyha; Colleen Ngai; Tiffany Thomas; Stephen Holleran; Rajasekhar Ramakrishnan; Wahida Karmally; Renu Nandakumar; Nelson Fontanez; Joseph Obunike; Santica M Marcovina; Alice H Lichtenstein; Nirupa R Matthan; James Matta; Magali Maroccia; Frederic Becue; Franck Poitiers; Brian Swanson; Lisa Cowan; William J Sasiela; Howard K Surks; Henry N Ginsberg
Journal:  Circulation       Date:  2016-12-16       Impact factor: 29.690

4.  Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.

Authors:  Dick C Chan; Gerald F Watts; Blai Coll; Scott M Wasserman; Santica M Marcovina; P Hugh R Barrett
Journal:  J Am Heart Assoc       Date:  2019-04-02       Impact factor: 5.501

Review 5.  The metabolism of lipoprotein (a): an ever-evolving story.

Authors:  Gissette Reyes-Soffer; Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2017-07-18       Impact factor: 5.922

6.  Effective cholesterol lowering after myocardial infarction in patients with nephrotic syndrome may require a multi-pharmacological approach: a case report.

Authors:  Simon Sjuls; Ulf Jensen; Karin Littmann; Annette Bruchfeld; Jonas Brinck
Journal:  Eur Heart J Case Rep       Date:  2021-05-13

Review 7.  Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule.

Authors:  Motasim M Jawi; Jiri Frohlich; Sammy Y Chan
Journal:  J Lipids       Date:  2020-02-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.